These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 10485081)

  • 1. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.
    Tod M; Mentré F; Merlé Y; Mallet A
    J Pharmacokinet Biopharm; 1998 Dec; 26(6):689-716. PubMed ID: 10485081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of using a robust optimality criterion in model based adaptive optimization.
    Strömberg EA; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):317-324. PubMed ID: 28386710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV.
    Montepiedra G; Svensson EM; Wong WK; Hooker AC
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):270-280. PubMed ID: 37946698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A constrained optimum adaptive design for dose finding in early phase clinical trials.
    Alam MI; Bogacka B; Coad DS
    J Biopharm Stat; 2024 Jul; ():1-26. PubMed ID: 38984691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Optimal Design Methods in Inverse Problems.
    Banks HT; Holm K; Kappel F
    Inverse Probl; 2011 Jul; 27(7):. PubMed ID: 21857762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, optimization, and inference of multiphasic decay of infectious virus particles.
    Seurat J; Gerbino KR; Meyer JR; Borin JM; Weitz JS
    bioRxiv; 2024 Feb; ():. PubMed ID: 38464262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time.
    Baklouti S; Concordet D; Borromeo V; Pocar P; Scarpa P; Cagnardi P
    Front Pharmacol; 2021; 12():634404. PubMed ID: 33995036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.
    Michelet R; Dossche L; De Bruyne P; Colin P; Boussery K; Vande Walle J; Van Bocxlaer J; Vermeulen A
    Clin Pharmacokinet; 2016 Sep; 55(9):1159-70. PubMed ID: 27106176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-optimal designs for parameter estimation for indirect pharmacodynamic response models.
    Khinkis LA; Krzyzanski W; Jusko WJ; Greco WR
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):523-39. PubMed ID: 19904585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.
    Silber HE; Nyberg J; Hooker AC; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):281-95. PubMed ID: 19554431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous optimal experimental design on dose and sample times.
    Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):125-45. PubMed ID: 19319484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.
    Landersdorfer CB; Bulitta JB; Kinzig M; Holzgrabe U; Sörgel F
    Clin Pharmacokinet; 2009; 48(2):89-124. PubMed ID: 19271782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.
    Chenel M; Bouzom F; Aarons L; Ogungbenro K
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):635-59. PubMed ID: 19130188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitation of drug evaluation in children by population methods and modelling.
    Tod M; Jullien V; Pons G
    Clin Pharmacokinet; 2008; 47(4):231-43. PubMed ID: 18336053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of uncertainty parameters estimated by different population PK software and methods.
    Dartois C; Lemenuel-Diot A; Laveille C; Tranchand B; Tod M; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):289-311. PubMed ID: 17216368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.
    Chenel M; Ogungbenro K; Duval V; Laveille C; Jochemsen R; Aarons L
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):737-56. PubMed ID: 16341474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size computations for PK/PD population models.
    Kang D; Schwartz JB; Verotta D
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):685-701. PubMed ID: 16284914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of individual and population designs using Splus.
    Retout S; Mentré F
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.